Short answer
Penumbra Inc (PEN) filed its Q2 2019 10-Q quarterly report on Aug 6, 2019 for the quarter ended Jun 30, 2019.
Penumbra Inc Q2 2019 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q2 revenue $134.2M, up 22.4% YoY from $109.6M
- Gross margin 70.0% vs 65.9%; operating margin 9.5% vs 8.5% YoY
- Best segment: Vascular revenue $52.7M, up 48.6%; weakest growth: Neuro revenue $81.5M, up 9.9%
- Cash $77.3M vs $67.9M; marketable investments $110.0M vs $133.0M
- Six-month operating cash flow $(0.2)M vs $10.8M; planned investments in products, manufacturing and international expansion, with quarterly variability expected
Risk Factors
- No material changes or new risk factors identified since the December 31, 2018 Form 10-K
- Regulatory risk: product approvals or clearances may be delayed or unavailable
- Competitive risk: large, well-capitalized competitors pressure physician adoption
- Operational risk: new-product launches require inventory buildup and salesforce expansion
- Currency risk: 35.7% of six-month revenue generated internationally without hedging
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Penumbra Inc quarterly reports
- Q3 2019 10-QFiled Nov 7, 2019
- Q1 2019 10-QFiled May 7, 2019
- Q3 2018 10-QFiled Nov 5, 2018
- Q2 2018 10-QFiled Aug 7, 2018
- Q1 2018 10-QFiled May 8, 2018
- Q3 2017 10-QFiled Nov 7, 2017
- Q2 2017 10-QFiled Aug 8, 2017
- Q1 2017 10-QFiled May 9, 2017
- Q3 2016 10-QFiled Nov 3, 2016
- Q2 2016 10-QFiled Aug 9, 2016
- Q1 2016 10-QFiled May 9, 2016
- Q3 2015 10-QFiled Nov 12, 2015
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.